531 related articles for article (PubMed ID: 36064592)
1. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
[TBL] [Abstract][Full Text] [Related]
2. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Mease PJ; Gladman DD; Poddubnyy D; Chakravarty SD; Shawi M; Kollmeier AP; Xu XL; Xu S; Deodhar A; Baraliakos X
Rheumatol Ther; 2023 Dec; 10(6):1637-1653. PubMed ID: 37819505
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.
Mease PJ; Helliwell PS; Gladman DD; Poddubnyy D; Baraliakos X; Chakravarty SD; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Sweet K; Shawi M; Karyekar CS; Deodhar A; van der Heijde D
Lancet Rheumatol; 2021 Oct; 3(10):e715-e723. PubMed ID: 38287608
[TBL] [Abstract][Full Text] [Related]
6. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Schiopu E; Chakravarty SD; Kollmeier AP; Xu XL; Shawi M; Jiang Y; Sheng S; Wang Y; Xu S; Merola JF; McInnes IB; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296534
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
[TBL] [Abstract][Full Text] [Related]
8. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
Rahman P; Mease PJ; Helliwell PS; Deodhar A; Gossec L; Kavanaugh A; Kollmeier AP; Hsia EC; Zhou B; Lin X; Shawi M; Karyekar CS; Han C
Arthritis Res Ther; 2021 Jul; 23(1):190. PubMed ID: 34261541
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
[TBL] [Abstract][Full Text] [Related]
12. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
[TBL] [Abstract][Full Text] [Related]
13. The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters.
Gezer HH; Duruöz MT
Int J Rheum Dis; 2022 Apr; 25(4):433-439. PubMed ID: 35080124
[TBL] [Abstract][Full Text] [Related]
14. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
[TBL] [Abstract][Full Text] [Related]
15. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
Clin Rheumatol; 2024 Jun; ():. PubMed ID: 38844682
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
[TBL] [Abstract][Full Text] [Related]
18. Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis.
van der Heijde D; Sieper J; Maksymowych WP; Brown MA; Lambert RG; Rathmann SS; Pangan AL
Arthritis Rheumatol; 2014 Mar; 66(3):667-73. PubMed ID: 24574227
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial.
Proft F; Torgutalp M; Muche B; Rios Rodriguez V; Verba M; Poddubnyy D
BMJ Open; 2021 Nov; 11(11):e048647. PubMed ID: 34785545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
